GE HealthCare price target lowered to $82 from $95 at BTIG

BTIG analyst Ryan Zimmerman lowered the firm’s price target on GE HealthCare (GEHC) to $82 from $95 and keeps a Buy rating on the shares. From Q4 to Q1 results, GE HealthCare shares fell by as much as 37.2% as the company faced significant exposure to global trade-war dynamics, and concerns on imaging demand, rare-earth metal export limitations, anti-dumping investigations, and other dynamics put GE HealthCare squarely in the cross-hairs, the analyst tells investors in a research note. The firm noted that the company provided a clear explanation of the entire impact of tariffs and set a “worse-case” scenario in the firm’s view based on tariffs as they stand today. While guidance reflects the new reality, as the macro environment improves, the firm thinks shares will climb back to prior levels.